Consumer genomic testing (CGT) can be defined as DNA tests sold or marketed directly to consumers for recreational, ancestry-related, or health-related purposes. Direct-to-consumer (DTC) testing does not typically involve a health professional in the selection of testing and return of test results, whereas consumer-driven genomic testing may involve a physician or other health professional who could have a financial relationship with the testing company. CGT has been part of the landscape of biomedicine for several decades.1 The earliest examples of these tests included DNA testing of a small number of single-nucleotide variations (SNVs) associated with nutritional status, drug metabolism, and mental health risk. Some of these tests were controversial; for example, tests that measured SNVs to predict risk of developing depression were criticized by geneticists, ethicists, and government regulators.2
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Feero WG, Wicklund CA. Consumer Genomic Testing in 2020. JAMA. 2020;323(15):1445–1446. doi:10.1001/jama.2020.3525
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: